Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVG-111 in Relapsed/Refractory ROR1+ Malignancies
NCT04763083Phase 1Recruiting
- Sponsor
- NovalGen
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NVG-111 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and 4 more (2 arms), sponsored by NovalGen. Primary endpoints: Treatment-emergent adverse events at 10 months, Serious adverse events at 10 months and 5 more. Started May 2021; status: recruiting.
02
Drugs
NVG-111
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04763083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04763083.